Niederer Kraft Frey AG | View firm profile
Niederer Kraft Frey advised PolyPeptide Group AG (SIX: PPGN) on the securing of additional financing under its revolving credit facility, as well as further support from its main shareholder.
With UBS as the coordinator and agent, the bank consortium including Danske Bank and Zürcher Kantonalbank have agreed to increase the available capital commitments by EUR 40 million to EUR 151 million and extend the term of its existing revolving credit facility (RCF) to March 2028. In parallel, Draupnir Holding B.V. has strengthened its support as the Group’s main shareholder and extended the term of the existing amounts outstanding under its unsecured short-term facility with the group. The agreements enhance the Group’s financial flexibility, as it continues its growth journey toward doubling 2023 revenue by 2028.
PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialised Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange
The NKF team was led by M&A/Finance partner Philip Spoerlé, working with associate Selim Lötscher and junior associate Selim Tisli (both M&A/Finance).